Vaccines saved 154 million lives, but coverage stalled

View organization page for The Lancet Group

185,425 followers

In the past 50 years, routine childhood vaccines have saved an estimated 154 million lives.* Despite this significant health achievement, childhood vaccination coverage has stalled in recent decades, leaving millions of children at risk for vaccine-preventable diseases. ✅ Between 1980 and 2023, vaccine coverage doubled for diseases such as diphtheria, tetanus, whooping cough (pertussis), measles, polio, and tuberculosis. ✅ There was also a 75% global decline in the number of children who had never received a routine childhood vaccine. However, since 2010, progress has stalled or reversed in many countries. The COVID-19 pandemic has contributed to this, making access and uptake more challenging. Today, vaccine coverage varies widely across regions. 💡 To reach global immunisation targets and protect more children, the following strategies are essential: - Targeted and equitable immunisation approaches - Strengthening primary healthcare systems - Building resilience against vaccine misinformation - Understanding and addressing vaccine hesitancy For regional and country-specific data, read the #GBDStudy in full 👉 hubs.li/Q03tvZ240 -- 🖼️ Figure 1 below: Global and super-regional estimates of vaccine coverage over time. Mean global (A) and super-regional (B) coverage estimates for the target age population by year for each vaccine, with 95% uncertainty intervals. The dashed horizontal line indicates the coverage required to meet the IA2030 goal of 90% coverage for life-course vaccines. Find out more in the paper. *The global progress in vaccinating children against life-threatening diseases began with the World Health Organization’s establishment of the Expanded Programme on Immunization (EPI) in 1974. Access the study in the comments.

  • No alternative text description for this image

We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! https://oncodaily.com/url/318593

Like
Reply
Sonali Abner Daniel

Climate Health Expert | AI/ML for Health Risk Forecasting | MNCH, Nutrition & Systems Strengthening Specialist

1w

It will be good to mention the type of vaccines in routine immunization...which are part of National Immunization Program.

Like
Reply
Prof. Abdelazeem Algammal

Professor and Head of Microbiology and Immunology Department. Associate Editor at BMC Microbiology & BMC Infectious Diseases. Listed in the Stanford University"World's Top 2% Scientists"|GBD Senior Collaborator (IHME)

1w

#In this study: #(1) We assessed the effect of the COVID-19 pandemic on routine childhood immunisation from 2020 to 2023 by comparing declines in coverage attributable to the COVID-19 pandemic with coverage levels expected in the absence of the pandemic. #(2) Rigorously evaluated progress needed to reach the IA2030 goal of a 50% reduction in numbers of zero-dose children (proxied as children younger than 1 year who have never received a dose of DTP1). # (3) Forecasted the plausibility of reaching IA2030's 90% global coverage targets for life-course vaccines by generating forecasts of DTP3, PCV3, and MCV2 coverage for 2030—the last representing the first forecasts published for PCV3 and MCV2 coverage.

Vaccination is not just a medical intervention; it’s a reflection of whether health systems are reaching the most vulnerable. When we see declining or uneven coverage, it often signals broader issues: inequity, misinformation, and loss of public trust. To restore momentum, we’ll need supply chains and logistics. We’ll need local dialogue, listening to communities, and investing in primary care that earns people’s confidence.

Laurence Delhaes

Prof - Head of Parasitology-Mycology department of Bordeaux Hospital Head of National Reference Center of Chronic Aspergillosis Heard of the Micro-Mycobiome research axis - Team 2 : Bronchial Remodeling - Inserm U1045

1w

An excellent paper that reminds how vaccinations are definitively usefull and safe

Amanda Fitzhugh

Pharmacy Manager (PharmD) | Aspiring Medical Science Liaison | Clinical Educator | Immunization Strategist | Skilled Scientific Communicator

1w

Stalled progress after decades of gains highlights just how fragile vaccine coverage can be. Local context and targeted strategies are now more important than ever for reaching those last gaps.

Gamal Saleh

Global Business Leader | Non-Executive Director | Strategic Advisor | Healthcare Innovator | Mentor & Coach

4h

Thx for Sharing Dr Piyali , very interested unsurprised data specaily low coverage for essential vaccination specially in LIC and MIC countries for all reasons mentions + another negatively impacted group ( Anti-vaccines ) all supranational groups and multinational cos has to work together for global advocacy strategy to address all issues beside vaccines hesitancy !

Like
Reply
Prof. Abdelazeem Algammal

Professor and Head of Microbiology and Immunology Department. Associate Editor at BMC Microbiology & BMC Infectious Diseases. Listed in the Stanford University"World's Top 2% Scientists"|GBD Senior Collaborator (IHME)

1w

#The number of zero-dose children, proxied as children younger than 1 year who do not receive DTP1, decreased by 74·9% globally between 1980 and 2019, with most of those declines reached during the 1980s and the 2000s. After 2019, counts of zero-dose children rose to a COVID 19-era peak of 18·6 million in 2021. #Most zero-dose children remain concentrated in conflict-affected regions and those with various constraints on resources available to put towards vaccination services, particularly sub-Saharan Africa. As of 2023, more than 50% of the 15·7 million (14·6–17·0) global zero-dose children resided in just eight countries (Nigeria, India, Democratic Republic of the Congo, Ethiopia, Somalia, Sudan, Indonesia, and Brazil), emphasising persistent inequities.

Prof. Abdelazeem Algammal

Professor and Head of Microbiology and Immunology Department. Associate Editor at BMC Microbiology & BMC Infectious Diseases. Listed in the Stanford University"World's Top 2% Scientists"|GBD Senior Collaborator (IHME)

1w

It is my pleasure to participate as a GBD Senior Collaborator in this significant study. Congratulations to all the GBD team ❤🤍

See more comments

To view or add a comment, sign in

Explore topics